Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder

NCT06041646 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Bipolar Disorder
Schizophrenia
Agitation,Psychomotor
Schizo Affective Disorder
Schizophreniform Disorders

Interventions

DRUG: Sublingual film containing Igalmi

Sponsor

BioXcel Therapeutics Inc

Collaborators

[object Object]